
SANGAMO THERAPEUTICS, INC SGMO
SANGAMO THERAPEUTICS, INC statistics & valuation
Net margin-310.8%
FCF margin-246.0%
Return on capital-701.7%
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Net margin (%)Gross margin (%)Operating margin (%)Return on equity (%)Shares outstandingNet debt ($)Share buybacks ($)Return on assets (%)Free cash flow margin (%)Debt / equity (×)EPS ($) Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Operating margin | -306.5% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% | -102.7% | -91.4% | -154.1% | -374.2% |
| Net margin | -310.8% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% | -92.9% | -80.9% | -149.2% | -369.6% |
| FCF margin | -246.0% | -116.6% | -139.6% | -219.0% | -231.7% | 131.3% | -161.2% | -7.7% | 20.3% | -343.6% |
| Return on assets | -205.8% | -96.4% | -156.0% | -34.2% | -24.7% | -12.9% | -14.9% | -11.6% | -19.0% | -45.4% |
| Return on equity | 861.6% | -430.1% | -311.1% | -65.2% | -47.5% | -24.3% | -22.0% | -18.6% | -29.0% | -52.6% |
| Current ratio | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.54 | 11.25 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.